Drug Profile
Bexagliflozin - Theracos
Alternative Names: Bexagliflozin L-proline; BRENZAVVY; EGT-0001442; EGT-0001474; EGT-1442; THR-1442Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Theracos
- Class Antihyperglycaemics; Antihypertensives; Chlorobenzenes; Cyclopropanes; Ethers; Glucosides; Phenyl ethers; Pyrans; Small molecules
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase II/III Essential hypertension
Most Recent Events
- 15 Apr 2024 Efficacy data from a phase III trial in Type 2 diabetes mellitus released by Theracos
- 04 Aug 2023 Efficacy and adverse events data from a phase III trial in Type 2 diabetes mellitus (Adjunctive treatment) released by Theracos
- 13 Jul 2023 Launched for Type 2 diabetes mellitus (Adjunctive treatment) in USA (PO)